Whitehawk Therapeutics Appoints Dr. Margaret Dugan as CMO to Advance Oncology Development
- Whitehawk Therapeutics appoints Dr. Margaret Dugan as CMO to enhance its oncology therapeutic development.
- Dr. Dugan brings over 30 years of oncology drug development experience to advance Whitehawk's ADC portfolio.
- Her leadership is expected to expedite clinical study designs and improve patient outcomes in oncology treatments.
Whitehawk Therapeutics Strengthens Leadership with Appointment of Dr. Margaret Dugan as CMO
Whitehawk Therapeutics, Inc. makes a significant stride in its oncology therapeutic development by appointing Dr. Margaret Dugan as Chief Medical Officer (CMO), effective December 1, 2025. This strategic appointment is crucial as the company prepares to advance its advanced antibody drug conjugate (ADC) portfolio into clinical development. Dr. Dugan brings over 30 years of experience in global oncology drug development, with a strong focus on early-stage clinical initiatives and regulatory strategy, which aligns seamlessly with Whitehawk's mission to offer innovative cancer treatments.
Dr. Dugan's impressive background includes her leadership roles in overseeing more than 12 Phase 1 clinical programs and achieving key regulatory approvals for notable cancer therapies such as capmatinib and ceritinib. Her extensive tenure at Novartis, where she led the early development organization, has equipped her with the skills necessary to navigate complex clinical pathways. Under her guidance, numerous programs progressed from proof-of-concept to full clinical development, illustrating her adeptness in steering drug development processes. At Dracen Pharmaceuticals, Dr. Dugan not only advanced its first clinical program through Phase 1 but also secured Fast Track designation, showcasing her ability to propel projects through the regulatory landscape efficiently.
As Whitehawk Therapeutics looks to differentiate its ADC offerings, Dr. Dugan's expertise will be instrumental in refining clinical study designs and expediting the development process for its three-asset ADC portfolio. The company's focus on smart target selection and addressing current limitations in cancer treatments positions it to deliver next-generation therapies aimed at difficult-to-treat cancers. Dr. Dugan expresses enthusiasm about her new role, emphasizing her commitment to contributing to the company's mission of improving patient outcomes in oncology, which is vital given the urgent need for advancements in cancer therapies.
In addition to her role at Whitehawk, Dr. Dugan's prior experience at Schrödinger, where she successfully built the clinical function and advanced three Phase 1 assets into the clinic, underscores her capability in driving clinical programs forward. Her appointment not only enhances Whitehawk's leadership team but also solidifies the company’s position in the competitive oncology landscape.
With Dr. Dugan at the helm of clinical development, Whitehawk Therapeutics is poised to make significant advancements in its ADC initiatives, potentially transforming treatment options for patients battling challenging cancers. The appointment reflects a strategic move to leverage her extensive knowledge and experience in oncology, paving the way for innovative solutions in the evolving field of cancer therapeutics.